Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the floor at ARM’s Meeting on the Med 2026 in Rome, this episode brings together leading voices from across cell and gene therapy to ask what recent breakthroughs are telling us about the maturity of the field – and what still needs to change before transformative therapies can reach more patients worldwide.
Gene therapies are continuing to demonstrate their potential across a broader range of diseases, with Regeneron’s approval for inherited deafness marking another important milestone for the sector. As clinical value becomes increasingly clear – extending beyond oncology into sensory disorders, rare diseases, and other areas of high unmet need – industry leaders reflect on how far the field has come, and where the biggest hurdles remain.
Featuring insights from Jason Foster of Ori Biotech, Delara Motlagh of FUJIFILM Cellular Dynamics, Susan Nichols of Propel Biosciences, Miguel Forte of Kiji Therapeutics, Louis Cicchini of Cencora, and Alexa Crăciunescu of Autolomous, the discussion explores the evolving picture for advanced therapies: from innovative regulatory pathways and new reimbursement models to commercialization challenges, long-term sustainability, and the promise of emerging approaches such as in vivo therapies.
Watch the video below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
